share_log

Alliance Global Partners Maintains Buy on Tonix Pharmaceuticals, Lowers Price Target to $8

Benzinga ·  Aug 2, 2023 00:17

Alliance Global Partners analyst James Molloy maintains Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy and lowers the price target from $18 to $8.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment